Loading...
Under maintenance — back shortly
Anti-inflammatory/anti-fibrotic→TGF-β suppression in scleroderma
Atorvastatin's anti-inflammatory and anti-fibrotic pleiotropic effects may benefit scleroderma (systemic sclerosis) by suppressing TGF-β-driven fibrosis and endothelial dysfunction; a clinical trial assessing efficacy and anti-inflammatory effects in scleroderma patients (2024) provides direct evidence. This is a user-priority domain (systemic sclerosis).
“Objectives To assess the efficacy and anti-inflammatory effect of atorvastatin as an additive treatment among SD patients.”
— The additional effect of 5% atorvastatin shampoo in the treatment of adult patients with mild to moderate seborrheic dermatitis of the scalp: A prospective, randomised, double-blind trial. (2024)DOI